All news

Thermo Fisher Scientific (TMO) Expands Drug Development Services, Is The Stock Fully Valued?

Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash

Thermo Fisher Scientific (TMO) is seeing increased demand for its drug development services, evidenced by a recent contract win for a Phase 2 multiple sclerosis trial. Despite strong share price momentum and positive market sentiment around AI-linked life sciences tools, the stock is considered slightly overvalued based on a discounted cash flow model and P/E ratio comparison to industry averages.

Read original source

TMO company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.